China-based eye disorder specialist Arctic Vision has raised a $100 million Series B round led by Loyal Valley Capital. Tencent Holdings, Octagon Capital, and New World Development CEO Adrian Cheng also participated.
Korea’s Standigm, which provides artificial intelligence (AI) systems to biotech operators, has raised a $44.5 billion pre-IPO round led by SKS Private Equity and Daishin Privat Equity.
Addor Capital – a Chinese VC firm backed by Jiangsu High-Tech Investment Group, also known as Govtor Capital – has raised RMB1.56 billion ($241 million) for its second renminbi-denominated healthcare fund.
SciClone Pharmaceuticals, a Chinese drug developer privatized by a PE consortium at a valuation of $605 million in 2017, has relisted in Hong Kong and ended its first day of trading with a market capitalization of HK$12.7 billion ($1.64 billion).
Baring Private Equity Asia has agreed to sell the surgical devices business of Lumenis, an Israel-headquartered company that counts Asia as its largest market, to Boston Scientific for $1.07 billion in cash.
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
Chinese middle-market buyout firm Lunar has agreed to acquire a women’s health and IVF business from Mason Group, a Hong Kong conglomerate with interests in financial services and healthcare, for HK$268 million ($34.5 million).
WuXi Diagnostics, a joint venture China diagnostics business set up by Hong Kong-listed pharmaceutical outsourcing giant WuXi AppTec and US-based Mayo Clinic has completed a $150 million Series B funding round.
Asia and Africa-focused impact investor LeapFrog Investments has recruited Biju Mohandas as a partner and global co-lead for healthcare.
Chengdu-based Clover Biopharmaceuticals has raised $230 million in Series C funding led by GL Ventures and Temasek Holdings. Oceanpine Capital, OrbiMed, and Delos Capital all re-upped.
AnchorDx, a China-based medical technology developer focused on DNA sequencing and diagnostics, has raised a $40 million Series C round led by OrbiMed and WuXi Huiying Investment.
Lilly Asia Ventures (LAV) has led a $90 million Series B round for Regor Therapeutics, a Chinese drug developer specializing in bioinformatics.
New Horizon Health, a China-based and venture capital-backed cancer early screening company, rose 215% on its trading debut following a HK$2 billion ($258 million) Hong Kong IPO.
CITIC Capital Partners has exited US-based dental business DDS Lab – the private equity firm’s first acquisition in the US as a lead investor – to RoundTable Healthcare Partners for an undisclosed sum.
Wuhan-based Binhui Biotech has raised RMB600 million ($93 million) in Series C funding led by Shenzhen-based Share Capital. Other investors include CICC Capital, Vertex Ventures China and Qianhai FOF under Shenzhen Capital Group.
CPE has backed a string of spinouts from Chinese medical device manufacturer MicroPort Medical. MicroPort CardioFlow Medtech’s Hong Kong IPO represents its first liquidity event
Cloud services provider Cloopen and biotech developer Adagene, both backed by Sequoia Capital China, have raised a combined $460 million in their US IPOs.
The New Frontier Group-led consortium that acquired Chinese hospital operator United Family Healthcare (UFH) through a special purpose acquisition company (SPAC) in 2019 is now looking to take the US-listed business private at a valuation of around $1.6...
Beijing Yuanxin Technology, operator of China-based online healthcare services platform Miaoshou Doctor, has raised RMB3 billion ($466 million) in Series E funding led by Sequoia Capital China and Tencent Holdings.
MBK Partners has joined the list of private equity firms pursuing deals in Japan’s aged care and healthcare space, having launched a tender offer for Tsukui Holdings Corporation at a valuation of JPY66.9 billion ($639 million).
Advent International has agreed to acquire Indian pharmaceuticals supplier ZCL Chemicals, setting up a minority exit for Morgan Stanley Private Equity Asia (MSPEA).
Te Puia Tapapa (TPT), a PE investor serving New Zealand indigenous groups, has backed a pathology business owned by New Zealand Superannuation Fund (NZ Super) and Ontario Teachers’ Pension Plan (OTPP).
The Carlyle Group and US GP Brighton Park Capital have committed a combined $200 million to Indegene, an Indian technology provider for the healthcare and life sciences industries.